Form 4: Baker Bros. Advisors Report Changes in Beneficial Ownership of Acadia Pharmaceuticals

Baker Bros. Advisors and related entities report transactions involving Acadia Pharmaceuticals stock, including acquisitions of restricted stock units and stock options, as well as pro rata distributions.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals (Julian C. Baker and Felix J. Baker), filed a Form 4 detailing changes in beneficial ownership of Acadia Pharmaceuticals Inc. (ACAD) stock.
• The report includes the acquisition of 18,774 restricted stock units (RSUs) for both Julian C. Baker and Dr. Stephen R. Biggar on May 29, 2024, under Acadia's 2024 Equity Incentive Plan.
• These RSUs vest on the earlier of May 29, 2025, or the date of the next annual meeting of stockholders, contingent on continuous service on the board.
• Additionally, 31,918 non-qualified stock options were granted to each of Julian C. Baker and Dr. Biggar, exercisable at $14.62, vesting quarterly from May 29, 2024, and expiring on May 28, 2034.
• The report also mentions in-kind pro rata distributions of common stock to Felix J. Baker and Julian C. Baker without consideration.
• After the reported transactions, Baker Bros. entities hold significant indirect beneficial ownership of Acadia Pharmaceuticals stock and options.
• The filing clarifies the relationships between Baker Bros. Advisors, its general partners, and the Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) regarding investment and voting power over the securities.
• Baker Bros. Advisors and related individuals disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The filing itself is a routine regulatory requirement. The acquisition of RSUs and stock options by key personnel suggests confidence, but it's not overtly bullish.

Positives

• The acquisition of RSUs and stock options by directors Julian C. Baker and Dr. Stephen R. Biggar signals confidence in Acadia Pharmaceuticals' future performance.
• The vesting schedule of the RSUs and stock options incentivizes long-term commitment from the directors.
• The continued significant holdings by Baker Bros. entities demonstrate their ongoing investment in Acadia Pharmaceuticals.

Future Outlook

The document does not contain explicit forward-looking statements about Acadia Pharmaceuticals' future performance, but the continued investment by Baker Bros. suggests a positive outlook.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market about their investment activities. Baker Bros. is a well-known healthcare investor, so their activity in Acadia Pharmaceuticals is noteworthy.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies, ensuring transparency regarding insider transactions.
• The vesting schedules and terms of the RSUs and stock options appear typical for executive compensation packages in the pharmaceutical industry.
• Comparing the holdings of Baker Bros. to other major institutional investors in Acadia Pharmaceuticals could provide further context on their relative influence.

Stakeholder Impact

• The reported transactions may influence investor sentiment towards Acadia Pharmaceuticals.
• The vesting of RSUs and stock options could potentially dilute existing shareholders' equity over time.

Key Dates